Early observations suggest
that the vehicle-treated Alzheimer's mice exhibit
a larger population
of reactive astrocytes, while the HT-ALZ
treated groups show fewer reactive
astrocytes, pointing to a potential breakthrough in the
treatment of Alzheimer's.
NEW YORK, Sept. 17,
2024 /PRNewswire/
-- Hoth Therapeutics, Inc. (NASDAQ: HOTH),
a biopharmaceutical company focused on developing innovative
treatments for unmet medical needs, today announced encouraging
preclinical results for its investigational Alzheimer's drug,
HT-ALZ. In a recent
study using Alzheimer's model mice treated
with varying doses of HT-ALZ, significant
reductions in astrocyte activity were observed in key areas of the
brain, suggesting a potential link between reduced reactive
astrocytes, and improved cognitive function.
In the study, astrocyte staining
was used to evaluate the impact of different
doses of aprepitant on
the hippocampus and cortex. The data showed
a notable decrease
in the percentage of area covered by
astrocytes in the hippocampus at both 20 mg and 40 mg dose levels,
compared to the vehicle- treated group. A similar trend
was observed in the cortex. These reductions in reactive
astrocytes corresponded with enhanced cognitive performance in the
same dose groups, further indicating that aprepitant's therapeutic
benefit may be tied to its impact on astrocytic activity.
Reactive astrocytes, which are typically larger than normal
astrocytes, play a role in the progression of neurodegenerative
diseases like Alzheimer's. Hoth Therapeutics is currently
conducting a secondary analysis to determine whether the size or
total number of astrocytes is changing as a result of treatment.
Early observations suggest that the
vehicle-treated Alzheimer's mice exhibit a larger population
of reactive astrocytes, while the HT-ALZ treated groups show fewer
reactive astrocytes, pointing to a potential breakthrough in the
treatment of Alzheimer's.
Robb Knie, CEO of Hoth
Therapeutics, stated "These preclinical results are a promising
step forward in our mission to develop effective therapies
for Alzheimer's disease. The reductions in astrocyte activity
and the corresponding improvements in cognitive function observed
with HT- ALZ give us confidence as we move forward in our
development process."
Hoth Therapeutics plans
to continue advancing HT-ALZ through further
studies and clinical trials, aiming to provide a novel
therapeutic option for patients suffering from Alzheimer's
disease. For more information on HT-ALZ and Hoth's innovative
pipeline, please visit our website.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please visit https://hoththerapeutics.com.
Forward-Looking Statement
This press release includes
forward-looking statements based
upon Hoth's current expectations, which may
constitute forward-looking statements for the purposes of the safe
harbor provisions under the Private Securities Litigation Reform
Act of 1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product
candidates and any other product
candidates we may develop, and the labeling
under any approval we may
obtain; the timing and costs of clinical trials,
and the timing
and costs of other expenses; market acceptance
of our products; the ultimate impact
of the current coronavirus pandemic,
or any other health epidemic, on our business,
our clinical trials, our research programs, healthcare systems, or
the global economy as a whole; our intellectual property; our
reliance on third-party organizations; our competitive position;
our industry environment; our anticipated financial and operating
results, including anticipated sources of revenues; our assumptions
regarding the size of the available market, benefits of our
products, product pricing, and timing of product launches;
management's expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans, and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct.
Actual results may differ materially from those indicated by these forward-looking statements as a result of
various important factors, including, without limitation,
market conditions and the
factors described in the section titled "Risk
Factors" in Hoth's most recent Annual Report on Form 10-K and
Hoth's other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-promising-preclinical-results-for-alzheimers-drug-ht-alz-302249998.html
SOURCE Hoth Therapeutics, Inc.